Predictive Validity of the Tiger Score for Daily-Life Disease Burden, Complications, and Medication Use in Ibd After 12-Month

The Toronto IBD Global Endoscopic Reporting (TIGER) score was developed to provide one endoscopic scoring index for patients with both Crohn's Disease (CD) and Ulcerative Colitis (UC); The goal of this study was to assess the TIGER score's predictive validity for daily-life disease burden (IBD Disk) and disease complications. A prospective 12-month study was conducted in one tertiary IBD center. Baseline colonoscopy was performed. Moderate-to-severe mucosal involvement was defined as a TIGER score ≥100, SES-CD >6, MES >1, and was utilized as a predictor for clinical outcomes. At each visit, IBD Disk questionnaires, disease complications, hospitalizations, surgeries, and medications were documented. A total of 107 adults, 52 with CD and 55 with UC, were included. Patients with a baseline TIGER score ≥100 had a significantly higher prevalence of an IBD Disk score ≥ 40 after the 12-month follow-up period despite receiving advanced therapy (33.9% vs. 7.8%, p<0.001). There were significantly more patients with a baseline TIGER score ≥100 who experienced at least one hospitalization (39.3% vs. 2.0%, p<0.001), underwent surgery (14.3% vs. 0.0%, p<0.005), had IBD-related complications (41.1% vs. 9.8%, p<0.001), required steroids (67.9% vs. 5.9%, p<0.001) or advanced therapy (85.7% vs. 7.8%, p<0.001). Similar significant results were obtained with SES-CD and MES as predictors of outcomes over the 12 months. The TIGER score is a simple endoscopic score for patients with CD and UC with an adequate predictive validity for worse clinical outcomes while having non-inferiority to the current best-referenced endoscopic scores.